AstraZeneca Wins Relief From $1075 Million Jury Award
Jury Verdict Overturned in Pfizer Patent Case
### Background On Friday, a Delaware federal jury ordered AstraZeneca to pay Pfizer $1075 million in damages for patent infringement. Pfizer's Wyeth unit claimed that AstraZeneca's heartburn drug Nexium infringed on two of its patents.### Judge's Ruling On Wednesday, a federal judge overturned the jury's verdict. The judge ruled that Pfizer had not proven that AstraZeneca infringed on the patents in question.
### Pfizer's Response Pfizer has expressed disappointment with the judge's ruling but has not yet announced whether it will appeal.
### Conclusion This case highlights the challenges of patent litigation in the pharmaceutical industry. It also shows that jury verdicts are not always final and that judges have the power to overturn them.
Comments